139 related articles for article (PubMed ID: 34779534)
21. Adaptive promising zone design for cancer immunotherapy with heterogeneous delayed treatment effect.
Li B; Yan F; Jiang D
J Biopharm Stat; 2024 Apr; ():1-20. PubMed ID: 38615361
[TBL] [Abstract][Full Text] [Related]
22. Robust group sequential designs for trials with survival endpoints and delayed response.
Ghosh P; Ristl R; König F; Posch M; Jennison C; Götte H; Schüler A; Mehta C
Biom J; 2022 Feb; 64(2):343-360. PubMed ID: 34935177
[TBL] [Abstract][Full Text] [Related]
23. Sample size calculation for testing differences between cure rates with the optimal log-rank test.
Wu J
J Biopharm Stat; 2017; 27(1):124-134. PubMed ID: 26882262
[TBL] [Abstract][Full Text] [Related]
24. Designing Late-Stage Randomized Clinical Trials with Cancer Immunotherapy: Can We Make It Simpler?
Chen TT
Cancer Immunol Res; 2018 Mar; 6(3):250-254. PubMed ID: 31343973
[TBL] [Abstract][Full Text] [Related]
25. Design and analysis of group-sequential clinical trials based on a modestly weighted log-rank test in anticipation of a delayed separation of survival curves: A practical guidance.
Magirr D; Jiménez JL
Clin Trials; 2022 Apr; 19(2):201-210. PubMed ID: 35257619
[TBL] [Abstract][Full Text] [Related]
26. On sample size calculation for comparing survival curves under general hypothesis testing.
Jung SH; Chow SC
J Biopharm Stat; 2012; 22(3):485-95. PubMed ID: 22416836
[TBL] [Abstract][Full Text] [Related]
27. Properties of the weighted log-rank test in the design of confirmatory studies with delayed effects.
Jiménez JL; Stalbovskaya V; Jones B
Pharm Stat; 2019 May; 18(3):287-303. PubMed ID: 30592138
[TBL] [Abstract][Full Text] [Related]
28. Designing therapeutic cancer vaccine trials with delayed treatment effect.
Xu Z; Zhen B; Park Y; Zhu B
Stat Med; 2017 Feb; 36(4):592-605. PubMed ID: 27807870
[TBL] [Abstract][Full Text] [Related]
29. Group sequential design with maximin efficiency robust test for immunotherapy with generalized delayed treatment effect.
Li B; Zhang J; Yang W; Su L; Yan F
Pharm Stat; 2024; 23(1):107-133. PubMed ID: 37859531
[TBL] [Abstract][Full Text] [Related]
30. Optimality of testing procedures for survival data in the nonproportional hazards setting.
Arfè A; Alexander B; Trippa L
Biometrics; 2021 Jun; 77(2):587-598. PubMed ID: 32535892
[TBL] [Abstract][Full Text] [Related]
31. Sample size and power for the weighted log-rank test and Kaplan-Meier based tests with allowance for nonproportional hazards.
Yung G; Liu Y
Biometrics; 2020 Sep; 76(3):939-950. PubMed ID: 31797363
[TBL] [Abstract][Full Text] [Related]
32. A sample size formula for the supremum log-rank statistic.
Eng KH; Kosorok MR
Biometrics; 2005 Mar; 61(1):86-91. PubMed ID: 15737081
[TBL] [Abstract][Full Text] [Related]
33. Phase II trial design with growth modulation index as the primary endpoint.
Wu J; Chen L; Wei J; Weiss H; Miller RW; Villano JL
Pharm Stat; 2019 Mar; 18(2):212-222. PubMed ID: 30458583
[TBL] [Abstract][Full Text] [Related]
34. Are non-constant rates and non-proportional treatment effects accounted for in the design and analysis of randomised controlled trials? A review of current practice.
Jachno K; Heritier S; Wolfe R
BMC Med Res Methodol; 2019 May; 19(1):103. PubMed ID: 31096924
[TBL] [Abstract][Full Text] [Related]
35. Sample size determination for the weighted log-rank test with the Fleming-Harrington class of weights in cancer vaccine studies.
Hasegawa T
Pharm Stat; 2014; 13(2):128-35. PubMed ID: 24497461
[TBL] [Abstract][Full Text] [Related]
36. In silico cancer immunotherapy trials uncover the consequences of therapy-specific response patterns for clinical trial design and outcome.
Creemers JHA; Ankan A; Roes KCB; Schröder G; Mehra N; Figdor CG; de Vries IJM; Textor J
Nat Commun; 2023 Apr; 14(1):2348. PubMed ID: 37095077
[TBL] [Abstract][Full Text] [Related]
37. Designing clinical trials with (restricted) mean survival time endpoint: Practical considerations.
Eaton A; Therneau T; Le-Rademacher J
Clin Trials; 2020 Jun; 17(3):285-294. PubMed ID: 32063031
[TBL] [Abstract][Full Text] [Related]
38. Treating non-responders: pitfalls and implications for cancer immunotherapy trial design.
Xu Z; Park Y; Liu K; Zhu B
J Hematol Oncol; 2020 Mar; 13(1):20. PubMed ID: 32171307
[TBL] [Abstract][Full Text] [Related]
39. Estimation of delay time in survival data with delayed treatment effect.
Li W; Chen SY; Rong A
J Biopharm Stat; 2019; 29(2):229-243. PubMed ID: 30359557
[TBL] [Abstract][Full Text] [Related]
40. Predicting analysis times in randomized clinical trials with cancer immunotherapy.
Chen TT
BMC Med Res Methodol; 2016 Feb; 16():12. PubMed ID: 26830911
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
